Z.M.D Group was established in August 2014. Z.M.D Group operates under two companies fully collaborated.
Z.M.D Diagnostics Ltd develops and commercializes an innovative early cancer detection and disease management platform based on its revolutionary discovery that cancer causes alterations in the function and composition of intestinal microflora in a quantifiable and measurable manner. To date, Z.M.D has developed a proprietary bioassay based on its core technology that has demonstrated effective clinical outcomes in vitro and during preliminary clinical studies. The Company is currently finalizing prototype development for its first product that will detect cancer of any kind and localization early.
Z.M.D Medical Ltd is a sister company of Z.M.D Diagnostics, develops and commercializes a therapeutic remedy to cure cancer of all types using the immune system.
Z.M.D Group expects a platform of product opportunities, both diagnostic and therapeutic, to be derived from its core technology in years to come.